Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027872 · ClinicalTrials.gov registry record · Phase 2
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT00027872: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00027872 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 125 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027872, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Phase II trial to study the effectiveness of tipifarnib in treating older patients who have previously untreated acute myeloid leukemia
Interventions
- OTHER laboratory biomarker analysis
- DRUG tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2001-10 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027872
The ClinicalTrials.gov registry entry for NCT00027872 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00027872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027872 about?
NCT00027872 is a clinical study titled "Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia". Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Phase II trial to study the effectiveness of tipifarnib in treating older patients who have previously untreated acute myeloid leukemia
What is the current status of trial NCT00027872?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2001-10. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00027872?
The interventions under investigation include: laboratory biomarker analysis (OTHER), tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00027872?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.